Medpace’s (MEDP) Neutral Rating Reiterated at Robert W. Baird

Medpace (NASDAQ:MEDP)‘s stock had its “neutral” rating reaffirmed by Robert W. Baird in a note issued to investors on Wednesday, Marketbeat.com reports. They currently have a $547.00 price target on the stock, up from their prior price target of $477.00. Robert W. Baird’s price target points to a potential upside of 0.13% from the company’s previous close.

A number of other research analysts also recently weighed in on the company. Royal Bank Of Canada dropped their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the company from $490.00 to $515.00 in a report on Tuesday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. BMO Capital Markets decreased their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Two equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $469.17.

Medpace Trading Down 3.3%

Shares of MEDP opened at $546.29 on Wednesday. The stock has a market capitalization of $15.60 billion, a P/E ratio of 34.34, a price-to-earnings-growth ratio of 2.87 and a beta of 1.15. The firm’s fifty day simple moving average is $460.02 and its two-hundred day simple moving average is $496.16. Medpace has a 12 month low of $306.70 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same period last year, the company posted $3.67 EPS. The business’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts predict that Medpace will post 17.04 EPS for the current fiscal year.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace in the 4th quarter worth about $30,000. Elyxium Wealth LLC purchased a new position in shares of Medpace in the 4th quarter worth about $30,000. Basecamp Wealth Advisors LLC grew its position in Medpace by 187.5% during the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after buying an additional 45 shares during the period. Finally, Quarry LP bought a new position in shares of Medpace during the 3rd quarter valued at approximately $35,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.